Compare M&T Bank Corporation (MTB) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs Revvity Inc — how do they compare? M&T Bank Corporation trades at $253.87 (market cap $36.42B), while Revvity Inc trades at $117.19 (market cap $12.91B). The key difference: M&T Bank Corporation is far larger — about 2.8× Revvity Inc's market cap, and M&T Bank Corporation pays the higher dividend (2.38%). Which is the better fit depends on your goals.
| MTB | RVTY | |
|---|---|---|
Market Cap | $36.42B | $12.91B |
Sector | Financials | Technology |
52-Week High | $254.04 | $117.75 |
52-Week Low | $178.63 | $82.26 |
Dividend Yield | 2.38% | 0.24% |
Enterprise Value | — | $15.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank (MTB) trades at $252.73, up 0.64% on the day, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings expectations in recent quarters, including Q2 2026 EPS of $5.35 versus $4.66 expected. Revenue growth and net interest income expansion support a solid profit margin of 30.85% for 2026. Analyst sentiment is mixed but leans positive, with a consensus price target of $255.92.
The outlook for MTB remains favorable due to robust earnings momentum and operational efficiency, though risks include potential interest rate volatility and competitive pressures in regional banking. The stock's current valuation at a P/E of 13.35 offers reasonable upside relative to peers, making it an attractive hold for investors seeking steady dividend income and growth.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
